Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00153166 · ClinicalTrials.gov registry record · Phase 2
ARREST PAD (Peripheral Arterial Disease)
A Phase 2 study, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 76
- Enrollment target
NCT00153166 is a Phase 2 study that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 76 participants.
The verdict
NCT00153166, a Phase 2 study, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 76 participants
- Enrollment target
Study Summary
This trial will test the hypothesis that inflammation and insulin resistance contribute to reduced walking distance in subjects with intermittent claudication by impairing vascular reactivity and skeletal muscle metabolic function.
Interventions
- DRUG atorvastatin and pioglitazone
- DRUG atorvastatin/placebo
- DRUG pioglitazone/placebo
- DRUG placebo/placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2004-01 |
| Est. Completion | 2011-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00153166
The ClinicalTrials.gov registry entry for NCT00153166 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which atorvastatin and pioglitazone is the first listed.
NCT00153166 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00153166 about?
NCT00153166 is a clinical study titled "ARREST PAD (Peripheral Arterial Disease)". This trial will test the hypothesis that inflammation and insulin resistance contribute to reduced walking distance in subjects with intermittent claudication by impairing vascular reactivity and skeletal muscle metabolic function.
What is the current status of trial NCT00153166?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 76 participants. The study started on 2004-01. Estimated completion is 2011-12.
What interventions are being tested in trial NCT00153166?
The interventions under investigation include: atorvastatin and pioglitazone (DRUG), atorvastatin/placebo (DRUG), pioglitazone/placebo (DRUG), placebo/placebo (DRUG).
Who is sponsoring clinical trial NCT00153166?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.